Merck & Co licenses early-stage cardiovascular programme targeting aldosterone synthase
This article was originally published in Scrip
Executive Summary
Merck & Co has obtained an exclusive worldwide licence to ElexoPharm's early-stage drug development programme targeting aldosterone synthase, a cytochrome P450 enzyme involved in the generation of aldosterone. Aldosterone is known to contribute to the development of cardiovascular diseases such as hypertension.